This was a randomized, double-masked, vehicle-controlled, Phase 3 study evaluating the efficacy and safety of OCS-01 QD compared to vehicle in the treatment of inflammation and pain following cataract surgery.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Absence of Anterior Chamber Cells at Visit 6.
Timeframe: Day 15
Absence of Ocular Pain at Visit 4.
Timeframe: Day 4